Loading...

Mark Lathrop

Home / Investigators  / Mark Lathrop

Mark Lathrop

Professor, Department of Human Genetics

Email: directoradmin.genome@mcgill.ca
Phone: (514) 398-6583

740 Dr Penfield Ave, Room 6105
Montréal, Québec, Canada, H3A 0G1

Professor Lathrop’s areas of research interest lie in the application of genomics and statistical methods to understand the molecular basis of human disease. He joined the McGill University in 2011 where he is Professor in the Department of Human Genetics and Scientific Director of the McGill University and Genome Quebec Innovation Centre. Dr. Lathrop was trained in theoretical statistics and genetics at the University of Washington. After obtaining his PhD, he moved to France where he was one of the founding members of the CEPH, which pioneered the international collaboration on the human genome in the 1980s and 1990s. In 1993, he moved to the University of Oxford, where he was a Wellcome Trust Principal Fellow and Professor of Human Genetics. At the University of Oxford he was the co-founder and first scientific director of the Wellcome Trust Centre for Human Genetics, an institute created to apply genomic approaches to understanding the molecular basis of human disease. At the request of the French government he returned to France in 1998 to found the centre National de Génotypage which developed into the principal national infrastructure for human genetic studies in France.. In 2005, the French government asked Pr. Lathrop to serve also as the scientific director of the Fondation Jean Dausset – Centre d’Etude du Polymorphism. He held these responsibilities until taking up his position at McGill.

Recent Publications

  • Routhier, J, Pons, S, Freidja, ML, Dalstein, V, Cutrona, J, Jonquet, A et al.. An innate contribution of human nicotinic receptor polymorphisms to COPD-like lesions. Nat Commun. 2021;12 (1):6384. doi: 10.1038/s41467-021-26637-6. PubMed PMID:34737286 PubMed Central PMC8568944.
  • Murall, CL, Fournier, E, Galvez, JH, N'Guessan, A, Reiling, SJ, Quirion, PO et al.. A small number of early introductions seeded widespread transmission of SARS-CoV-2 in Québec, Canada. Genome Med. 2021;13 (1):169. doi: 10.1186/s13073-021-00986-9. PubMed PMID:34706766 PubMed Central PMC8550813.
  • Le Grand, Q, Satizabal, CL, Sargurupremraj, M, Mishra, A, Soumaré, A, Laurent, A et al.. Genomic studies across the lifespan point to early mechanisms determining subcortical volumes. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; :. doi: 10.1016/j.bpsc.2021.10.011. PubMed PMID:34700051 .
  • Nakanishi, T, Pigazzini, S, Degenhardt, F, Cordioli, M, Butler-Laporte, G, Maya-Miles, D et al.. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021;131 (23):. doi: 10.1172/JCI152386. PubMed PMID:34597274 PubMed Central PMC8631592.
  • Nastase, A, Mandal, A, Lu, SK, Anbunathan, H, Morris-Rosendahl, D, Zhang, YZ et al.. Integrated genomics point to immune vulnerabilities in pleural mesothelioma. Sci Rep. 2021;11 (1):19138. doi: 10.1038/s41598-021-98414-w. PubMed PMID:34580349 PubMed Central PMC8476593.
  • COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021; :. doi: 10.1038/s41586-021-03767-x. PubMed PMID:34237774 .
  • Nakanishi, T, Cerani, A, Forgetta, V, Zhou, S, Allen, RJ, Leavy, OC et al.. Genetically increased circulating FUT3 level leads to reduced risk of Idiopathic Pulmonary Fibrosis: a Mendelian Randomisation Study. Eur Respir J. 2021; :. doi: 10.1183/13993003.03979-2020. PubMed PMID:34172473 .
  • Willis-Owen, SAG, Domingo-Sabugo, C, Starren, E, Liang, L, Freidin, MB, Arseneault, M et al.. Y disruption, autosomal hypomethylation and poor male lung cancer survival. Sci Rep. 2021;11 (1):12453. doi: 10.1038/s41598-021-91907-8. PubMed PMID:34127738 PubMed Central PMC8203787.
  • Kosmicki, JA, Horowitz, JE, Banerjee, N, Lanche, R, Marcketta, A, Maxwell, E et al.. Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. Am J Hum Genet. 2021;108 (7):1350-1355. doi: 10.1016/j.ajhg.2021.05.017. PubMed PMID:34115965 PubMed Central PMC8173480.
  • Povysil, G, Butler-Laporte, G, Shang, N, Wang, C, Khan, A, Alaamery, M et al.. Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. J Clin Invest. 2021;131 (14):. doi: 10.1172/JCI147834. PubMed PMID:34043590 PubMed Central PMC8279578.
Search PubMed